Go Back

Practical Guidance on Peptide Receptor Radionuclide Therapy (PRRNT) for Neuroendocrine Tumours

This book “Practical Guidance on Peptide Receptor Radionuclide Therapy (PRRNT) for Neuroendocrine Tumours” is a milestone providing a comprehensive multi-disciplinary guidance to  promote the standardized, effective and safe implementation of best practices for the treating of Neuroendocrine and Gastro-Entero-Pancreatic (GEP) tumours applying PRRNT either alone or in combination with other treatment options while taking into consideration most recent International classification of Neuroendocrine tumours.

This book embarks on providing comprehensive protocols for employing either Yttrium-90 or Lutetium-177 tagged somatostatin receptor-targeting peptides and clinically verified protocols for renal protection. It comprises a comprehensive compilation of medical evidence on top of clinical experience of renowned professionals. Furthermore, it contains clinical presentations, eligibility criteria and means of assessing effectiveness of therapy utilizing molecular and morphological medical imaging techniques. NET is a unique sub-class of cancer in which good percentage of affected patients may be treated successfully by PRRNT while improving their symptoms and their quality of life in the majority of cases. This book is a practical reference for specialists in Clinical Oncology and ion Nuclear Medicine embarking on deploying and executing a comprehensive programme for treating patients with neuroendocrine tumours. The Scientific secretary, Mr. J Zaknun, is indebted to the contribution of the experts whose names are listed in an alphabetic order at the end of this book.

It is currently under review so it should be considered as a draft version of the final publication which is not available yet on the IAEA publications site.

This is a non-editable and non-printable version but it can be freely downloaded.

In the near future the free complete PDF version of the publication will be available.